WO2002043708A3 - Magnetic particles for the targeted regional therapy - Google Patents

Magnetic particles for the targeted regional therapy Download PDF

Info

Publication number
WO2002043708A3
WO2002043708A3 PCT/EP2001/013926 EP0113926W WO0243708A3 WO 2002043708 A3 WO2002043708 A3 WO 2002043708A3 EP 0113926 W EP0113926 W EP 0113926W WO 0243708 A3 WO0243708 A3 WO 0243708A3
Authority
WO
WIPO (PCT)
Prior art keywords
magnetic particles
regional therapy
targeted regional
targeted
therapy
Prior art date
Application number
PCT/EP2001/013926
Other languages
German (de)
French (fr)
Other versions
WO2002043708A2 (en
Inventor
Christoph Alexiou
Christian Bergemann
Original Assignee
Christoph Alexiou
Christian Bergemann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christoph Alexiou, Christian Bergemann filed Critical Christoph Alexiou
Priority to EP01998333A priority Critical patent/EP1339396A2/en
Publication of WO2002043708A2 publication Critical patent/WO2002043708A2/en
Publication of WO2002043708A3 publication Critical patent/WO2002043708A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to magnetic particles that comprise a magnetic substance combined with a therapeutic substance. The particles according to the invention are used for the regional magnetotherapy of diseases by intra-arterial application.
PCT/EP2001/013926 2000-11-29 2001-11-28 Magnetic particles for the targeted regional therapy WO2002043708A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP01998333A EP1339396A2 (en) 2000-11-29 2001-11-28 Magnetic particles for the targeted regional therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10059151A DE10059151C2 (en) 2000-11-29 2000-11-29 Magnetic particles for targeted regional therapy and use of the same
DE10059151.5 2000-11-29

Publications (2)

Publication Number Publication Date
WO2002043708A2 WO2002043708A2 (en) 2002-06-06
WO2002043708A3 true WO2002043708A3 (en) 2002-09-06

Family

ID=7665032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/013926 WO2002043708A2 (en) 2000-11-29 2001-11-28 Magnetic particles for the targeted regional therapy

Country Status (3)

Country Link
EP (1) EP1339396A2 (en)
DE (1) DE10059151C2 (en)
WO (1) WO2002043708A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1610752B1 (en) * 2003-01-31 2013-01-02 Boston Scientific Limited Localized drug delivery using drug-loaded nanocapsules and implantable device coated with the same
DE10331439B3 (en) 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetic nanoparticles with improved magnetic properties
DE102004052533A1 (en) † 2004-10-15 2006-05-04 Mykhaylyk, Olga, Dr. Particles for use in diagnosis and therapy, especially for binding therapeutic agent for treating e.g. tumors and bacterial, rheumatic, neurologic and thrombotic diseases, have nanocrystalline magnetic core and envelope enclosing core
DE102005016873A1 (en) * 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag New nano-particle useful for production of composition to treatment and/or prophylaxis of proliferative illnesses, cancer and bacterial infections, where nano-particle is bonded therapeutic substance
DE102005039579B4 (en) 2005-08-19 2022-06-30 Magforce Ag Method for introducing therapeutic substances into cells
US20070281034A1 (en) * 2006-05-15 2007-12-06 Kirpotin Dmitri B Magnetic microparticles comprising organic substances
ES2393639T3 (en) 2007-01-21 2012-12-26 Hemoteq Ag Medical product to treat body duct closures and prevention of new closures
DE102008008522A1 (en) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantable nanoparticle-containing products
CZ301005B6 (en) * 2008-08-29 2009-10-14 Fyzikální ústav AV CR, v.v.i. Process for preparing hybrid nanoparticles from nanoparticle agglomerates of complex multicomponent metal oxides
EP2508171B1 (en) * 2011-03-25 2014-05-07 Universitätsklinikum Erlangen Pharmaceutical magnetic nano-particle composition
RU2554219C2 (en) * 2013-05-17 2015-06-27 Общество с ограниченной ответственностью "ТехноМикрон" Method of laser thermotherapy of skin and its appendages, pharmaceutical composition therefore and their application
WO2017187438A1 (en) * 2016-04-25 2017-11-02 Technion Research & Development Foundation Limited Targeted delivery of aerosols of magnetized active agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624426A1 (en) * 1996-06-19 1998-01-02 Christian Bergemann Magnetic particle for transport of diagnostic or therapeutic agent
US5928958A (en) * 1994-07-27 1999-07-27 Pilgrimm; Herbert Superparamagnetic particles, process for their manufacture and usage
WO2001056546A2 (en) * 2000-02-05 2001-08-09 Florida State University Research Foundation Magnetoliposome composition for targeted treatment of biological tissue

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5928958A (en) * 1994-07-27 1999-07-27 Pilgrimm; Herbert Superparamagnetic particles, process for their manufacture and usage
DE19624426A1 (en) * 1996-06-19 1998-01-02 Christian Bergemann Magnetic particle for transport of diagnostic or therapeutic agent
WO2001056546A2 (en) * 2000-02-05 2001-08-09 Florida State University Research Foundation Magnetoliposome composition for targeted treatment of biological tissue

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALEXIOU C ET AL: "Magnetic mitoxantrone nanoparticle detection by histology, X-ray and MRI after magnetic tumor targeting", JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 225, no. 1-2, 2001, pages 187 - 193, XP004234944, ISSN: 0304-8853 *
ALEXIOU CHRISTOPH ET AL: "Locoregional cancer treatment with magnetic drug targeting.", CANCER RESEARCH, vol. 60, no. 23, 1 December 2000 (2000-12-01), pages 6641 - 6648, XP001063184, ISSN: 0008-5472 *
ALEXIOU CHRISTOPH ET AL: "Magnetic drug targeting: An interdisciplinary method in treatment of cancer.", EUROPEAN BIOPHYSICS JOURNAL, vol. 29, no. 4-5, 2000, 3rd European Biophysics Congress;Munchen, Germany; September 09-13, 2000, pages 364, XP001068473, ISSN: 0175-7571 *
GUPTA P K ET AL: "MAGNETICALLY CONTROLLED TARGETED MICRO-CARRIER SYSTEMS", LIFE SCIENCES, vol. 44, no. 3, 1989, pages 175 - 186, XP002197845, ISSN: 0024-3205 *
GUPTA P K ET AL: "TARGETED DELIVERY OF LOW DOSE DOXORUBICIN HYDROCHLORIDE ADMINISTERED VIA MAGNETIC ALBUMIN MICROSPHERES IN RATS", JOURNAL OF MICROENCAPSULATION, vol. 7, no. 1, 1990, pages 85 - 94, XP002197846, ISSN: 0265-2048 *
LUBBE A S ET AL: "Physiological aspects in magnetic drug-targeting", JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 194, no. 1-3, April 1999 (1999-04-01), pages 149 - 155, XP004166660, ISSN: 0304-8853 *
PULFER S K; CICCOTTO S L; GALLO J M: "Distribution of small magnetic particles in brain tumor-bearing rats.", JOURNAL OF NEURO-ONCOLOGY, vol. 41, no. 2, January 1999 (1999-01-01), pages 99 - 105, XP002197848 *
PULFER S K; GALLO J M: "Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres", JOURNAL OF DRUG TARGETING, vol. 3, no. 6, 1998, pages 215 - 227, XP002197847 *

Also Published As

Publication number Publication date
EP1339396A2 (en) 2003-09-03
DE10059151C2 (en) 2003-10-16
DE10059151A1 (en) 2002-06-13
WO2002043708A2 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
WO2001030381A3 (en) Use of csf-1 inhibitors
IL169338A0 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
AU2002350235A1 (en) Combination bacteriolytic therapy for the treatment of tumors
EP1578421A4 (en) Pharmaceutical preparations for treatments of diseases and disorders of the breast
PL378108A1 (en) Combination therapy for the treatment of immunoinflammatory disorders
HK1078613A1 (en) Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
AU2001282717A1 (en) Cancer treatment by combination therapy
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
AU7295601A (en) Treatment of central nervous system diseases by antibodies against glatiramer acetate
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
EP1404343A4 (en) Therapeutic combinations for the treatment of hormone deficiencies
AU2002343739A1 (en) Improved therapy for topical diseases
WO2002043708A3 (en) Magnetic particles for the targeted regional therapy
AU2002334870B8 (en) Combinations for the treatment of immunoinflammatory disorders
IL159887A0 (en) Combination therapy for the treatment of cancer
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU5937901A (en) Combination therapy of respiratory diseases using antibodies
GB0004531D0 (en) The treatment of respiratory diseases
IL153831A (en) Pharmaceutical composition for therapy of neurodegenerative disease of the brain
WO2001097855A3 (en) Targeted combination immunotherapy of cancer and infectious diseases
HRP20030677A2 (en) Methods of administering epothilone analogs for the treatment of cancer
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
ZA200505996B (en) Combination therapy for the treatment of immunoinflammatory disorders
AU2002218977A1 (en) Novel marker for the diagnosis and therapy of tumours
AU2002325721A1 (en) Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001998333

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001998333

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001998333

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP